Angelo De Milito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8421822/publications.pdf Version: 2024-02-01



ANCELO DE MILITO

#	Article	IF	CITATIONS
1	Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34. Autophagy, 2020, 16, 2110-2111.	4.3	25
2	Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy. Science Advances, 2020, 6, eaax7881.	4.7	164
3	STAT3 is activated in multicellular spheroids of colon carcinoma cells and mediates expression of IRF9 and interferon stimulated genes. Scientific Reports, 2019, 9, 536.	1.6	9
4	Spheroidâ€based 3D cell cultures identify salinomycin as a promising drug for the treatment of chondrosarcoma. Journal of Orthopaedic Research, 2018, 36, 2305-2312.	1.2	19
5	A drug screening assay on cancer cells chronically adapted to acidosis. Cancer Cell International, 2018, 18, 147.	1.8	27
6	Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Cancer Metabolism. Frontiers in Oncology, 2018, 8, 329.	1.3	3
7	Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. Cancer Letters, 2018, 435, 32-43.	3.2	93
8	Therapeutic implications of tumor interstitial acidification. Seminars in Cancer Biology, 2017, 43, 119-133.	4.3	82
9	Pathobiology and Therapeutic Implications of Tumor Acidosis. Current Medicinal Chemistry, 2017, 24, 2827-2845.	1.2	10
10	Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance. Oncotarget, 2016, 7, 63408-63423.	0.8	78
11	Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics. Trends in Cancer, 2016, 2, 657-663.	3.8	17
12	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. Cancer Research, 2016, 76, 3166-3178.	0.4	48
13	Metabolism and microenvironment in cancer plasticity. Cancer & Metabolism, 2016, 4, .	2.4	12
14	The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells. Stem Cell Reviews and Reports, 2016, 12, 621-633.	5.6	91
15	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
16	Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells. Oncotarget, 2016, 7, 35703-35723.	0.8	30
17	Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs. International Journal of Cancer, 2015, 136, E51-61.	2.3	28
18	Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. International Journal of Molecular Sciences, 2015, 16, 27313-27326.	1.8	53

Angelo De Milito

#	Article	IF	CITATIONS
19	Proton channels and exchangers in cancer. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2715-2726.	1.4	158
20	Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine. Autophagy, 2014, 10, 562-571.	4.3	176
21	Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter. Autophagy, 2014, 10, 57-69.	4.3	3
22	Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications, 2014, 5, 3295.	5.8	197
23	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncolmmunology, 2013, 2, e22058.	2.1	121
24	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.4	470
25	Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress. Journal of Biological Chemistry, 2012, 287, 30664-30676.	1.6	153
26	A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents. Current Pharmaceutical Design, 2012, 18, 1395-1406.	0.9	50
27	Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Immunology, 2007, 123, 070720050330001-???.	2.0	26
28	Primary HIV-1 Infection Sets the Stage for Important B Lymphocyte Dysfunctions. Retrovirology, 2005, 2, P95.	0.9	6
29	Title is missing!. Retrovirology, 2005, 2, P84.	0.9	2
30	Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. Aids, 2001, 15, 1109-1113.	1.0	14
31	Loss of memory (CD27) B lymphocytes in HIV-1 infection. Aids, 2001, 15, 957-964.	1.0	185
32	Cross-linking of LFA-1 molecule enhances Fas mediated apoptosis of Jurkat and Burkitt lymphoma cell lines. Cell Death and Differentiation, 2001, 8, 1123-1124.	5.0	2
33	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2000, 16, 1379-1384.	0.5	18
34	Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients. , 1999, 57, 140-144.		33
35	Development and Significance of the HIV-1 Reverse Transcriptase M184V Mutation During Combination Therapy With Lamivudine, Zidovudine, and Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 203.	0.9	19
36	Clinical Evaluation of an In-House Reverse Transcription-Competitive PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. Journal of Clinical Microbiology, 1999, 37, 333-338.	1.8	10

ANGELO DE MILITO

#	Article	IF	CITATIONS
37	Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Molecular Biotechnology, 1998, 10, 1-8.	1.3	22
38	HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Human Pathology, 1998, 29, 1285-1289.	1.1	55
39	Nerve Growth Factor Released by CD40 Ligand-Transfected L Cells: Implications for Functional and Phenotypic Studies on CD40+Cells. Blood, 1998, 92, 4482-4484.	0.6	3
40	Lack of Evidence of HHV-8 DNA in Blood Cells From Heart Transplant Recipients. Blood, 1997, 89, 1837-1838.	0.6	3
41	Increased reliability of selective PCR by using additionally mutated primers and a commercialTaq DNA polymerase enhancer. Molecular Biotechnology, 1995, 3, 166-169.	1.3	7
42	Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction. Molecular and Cellular Probes, 1995, 9, 321-326.	0.9	12